Drug manufacturers Sanofi and Regeneron Pharmaceuticals have agreed that Dupixent cancer lawsuits should be consolidated into a multidistrict litigation (MDL) in the United States District Court for the Northern District of Georgia. This consolidation represents a significant development in the emerging litigation surrounding Dupixent, an immunosuppressant medication used to treat eczema, asthma, and other allergic conditions, after multiple patients developed cutaneous T-cell lymphoma (CTCL) and other lymphomas following its use. In March 2026, attorneys representing three victims filed a motion with the Judicial Panel on Multidistrict Litigation requesting the consolidation, and the drug makers’ agreement to this consolidation reflects the growing body of evidence linking Dupixent to serious cancer risks.
The MDL consolidation is being pursued because a significant portion of cases have already been filed in the Georgia federal court—over 25% of all Dupixent cancer cases as of February 2026—making it the logical venue for centralized litigation. The consolidation process will streamline discovery, reduce duplicative litigation, and potentially lead to more efficient case resolution for injured patients. This article explains why these lawsuits are being combined, what the MDL means for plaintiffs, and what evidence has sparked this litigation in the first place.
Table of Contents
- Why Are Drug Makers Agreeing to Consolidate Dupixent Cancer Lawsuits?
- What Evidence Triggered FDA Alerts and Litigation?
- What Is the Timeline of Dupixent Cancer Litigation?
- What Does MDL Consolidation Mean for Plaintiffs?
- What Is the Current Legal Status of Dupixent Cancer Claims?
- Which Manufacturers Face Dupixent Cancer Lawsuits?
- What Is the Future Outlook for Dupixent Cancer Litigation?
- Conclusion
Why Are Drug Makers Agreeing to Consolidate Dupixent Cancer Lawsuits?
Multidistrict litigations (MDLs) are consolidations of similar lawsuits filed across the country that are transferred to a single federal court for coordinated pretrial proceedings. The primary reason manufacturers and plaintiffs’ attorneys pursue MDL consolidation is efficiency: rather than litigating identical claims across dozens of courts, a single judge oversees discovery, motions, and case management. For Dupixent cancer cases, consolidation in Georgia makes practical sense because a critical mass of cases has already accumulated there, and attorneys representing victims filed their formal motion with the Judicial Panel on Multidistrict Litigation in March 2026 specifically requesting this federal court venue. The agreement by Sanofi and Regeneron to consolidation is notable because it indicates the manufacturers recognize the strength and scope of the emerging litigation against them. Unlike some mass tort defendants who resist consolidation to slow the litigation process, accepting an MDL suggests the manufacturers may be considering a broader settlement framework rather than fighting individual cases.
The Northern District of Georgia was chosen not only because 25% of cases were already pending there, but also because several experienced MDL judges in that court have managed complex pharmaceutical litigation, including other mass tort cases involving medication safety and failure to warn claims. However, consolidation does not mean Dupixent is definitively unsafe or that lawsuits will automatically succeed. An MDL simply provides a legal structure for managing multiple related cases. The consolidation allows plaintiffs’ attorneys to develop facts about the manufacturers’ knowledge of cancer risks, warnings provided to doctors and patients, and scientific evidence supporting causation. The manufacturers retain all legal defenses, including challenging whether Dupixent actually caused individual plaintiffs’ lymphomas, arguing that confounding health factors may have contributed, or asserting they provided adequate warnings.
What Evidence Triggered FDA Alerts and Litigation?
The Dupixent cancer litigation emerged after the FDA identified unusually high rates of cutaneous T-cell lymphoma (CTCL) and other lymphomas among patients using the drug. In March 2025, the FDA added Dupixent and CTCL to its Potential Signals of Serious Risks list based on more than 300 CTCL cases reported to the FDA Adverse Event Reporting System (FAERS) that were linked to Dupixent use. What makes this signal statistically alarming is the comparison: the rate of lymphoma reports involving Dupixent users was approximately 30 times higher than the rate for all other medications combined. Scientific research has further strengthened concerns about Dupixent and lymphoma risk. A study published in the European Respiratory Journal examining asthma patients found that those taking Dupixent had a 79% higher risk of developing lymphoma compared to asthma patients not using the drug.
More concerning, the same research found Dupixent was associated with a 4.5-fold increased risk of T cell and natural killer (NK) cell lymphomas, the specific cancer types appearing in lawsuits. These statistics represent relative risk increases—meaning a patient on Dupixent is roughly 4.5 times more likely to develop this rare cancer type than an unexposed person—rather than absolute risk, which would be the actual number of patients expected to develop cancer in a given population. However, it is important to note that Dupixent provides genuine therapeutic benefits for patients with severe eczema, asthma, and certain allergic conditions where other treatments have failed. The question for litigation and regulators is not whether Dupixent is useful—it is—but whether Sanofi and Regeneron adequately warned doctors and patients about cancer risks before prescribing the medication. If the manufacturers knew or should have known about these lymphoma risks and failed to disclose them to physicians, they may face liability for failing to warn. Conversely, if the cancer risks were genuinely unknown at the time patients were treated, manufacturers may argue they cannot be held liable for failing to warn about unknown risks.
What Is the Timeline of Dupixent Cancer Litigation?
The Dupixent cancer litigation is in its earliest stages, but the timeline of legal filings shows how quickly cases have accumulated. The first known wrongful death lawsuit was filed in October 2025 by a Tennessee woman’s family; she developed T-cell lymphoma months after beginning Dupixent treatment and subsequently died. This case drew national attention to the Dupixent-cancer connection and signaled to other injured patients and their families that legal action was possible. By February 2026, attorneys at Levin Papantonio, a major pharmaceutical litigation firm, filed a motion with the federal court system requesting that Dupixent cases be transferred to the United States District Court for the Northern District of Georgia. The attorneys noted that 25% or more of all Dupixent cancer lawsuits were already pending in that Georgia court, making consolidation there more efficient than spreading cases across multiple federal and state courts.
Just one month later, in March 2026, the same attorneys filed a more formal motion with the Judicial Panel on Multidistrict Litigation representing three specific victims who developed CTCL from Dupixent, requesting that the cases be consolidated in a federal MDL. As of March 2026, the Dupixent MDL has not yet been formally established, but the Judicial Panel is expected to rule on consolidation soon. No jury verdicts have been returned, and no settlements have been reached. This means we are still in the very early stages of litigation—before formal discovery, before expert reports, and before either side has fully developed its evidence. For plaintiffs already suing or considering filing a claim, this early stage offers both advantages (cases can still be filed) and disadvantages (litigation will likely take years to resolve).
What Does MDL Consolidation Mean for Plaintiffs?
For patients injured by Dupixent, MDL consolidation offers several practical advantages. First, it centralizes all discovery—the process of exchanging documents, taking depositions, and obtaining expert reports—under one judge. This prevents plaintiffs from having to prove the same facts about Dupixent’s cancer risks multiple times in different courts. Manufacturers must provide documents about their internal knowledge of lymphoma risks, their communications with regulatory agencies, and their instructions to sales representatives, just once to the MDL judge rather than to multiple judges across the country. Second, MDL consolidation often facilitates settlement negotiations. Once substantial discovery is complete and both sides understand the strength of the evidence, defendants are more likely to negotiate a global settlement affecting all plaintiffs in the MDL.
This settlement process can be faster and more certain than individual jury trials, though it typically results in lower individual payouts than an outlier jury verdict would provide. For example, if a bellwether trial (an initial test case) goes to trial in the MDL and returns a strong verdict for plaintiffs, manufacturers often agree to settle rather than face similar verdicts across hundreds of cases. However, consolidation in a single MDL also means individual plaintiffs lose control over their own case strategy. The MDL judge and a Plaintiff Steering Committee (selected attorneys representing the plaintiffs collectively) make decisions about discovery, expert selection, and settlement terms that bind all plaintiffs. A plaintiff may believe their specific case is stronger than others and prefer to try the case individually rather than accept a settlement negotiated for the group, but MDL procedures may prohibit opting out if a settlement is reached. For those already filed, the Dupixent MDL consolidation will streamline the path to resolution, but injured patients who have not yet filed should understand that joining an MDL means accepting group decision-making rather than pursuing an independent lawsuit.
What Is the Current Legal Status of Dupixent Cancer Claims?
As of March 2026, Dupixent cancer litigation is in the early investigation and filing stage. No federal MDL has been formally established yet, though the Judicial Panel is expected to rule on the consolidation motion in the coming weeks or months. The cases filed so far—the handful of lawsuits that have been publicly reported—are still in their infancy, with pleadings and initial motions being filed but discovery not yet fully underway. A critical limitation at this early stage is the lack of scientific consensus about Dupixent’s causation of individual cancers. While the FDA signal and European research show a statistical association between Dupixent use and lymphoma, statistical association is not the same as proof that Dupixent caused a specific person’s cancer.
A plaintiff claiming Dupixent caused his or her lymphoma must establish that Dupixent more likely than not caused their specific cancer, accounting for alternative explanations like genetic predisposition, prior exposures to carcinogens, or other medications they were taking. Medical experts retained by the plaintiffs will need to conduct detailed case-by-case causation analysis, which can be expensive and time-consuming. Moreover, the manufacturers will likely argue that they provided adequate warnings about lymphoma risks through FDA-required label changes. If Sanofi and Regeneron can demonstrate they warned prescribing physicians about lymphoma concerns as soon as they became aware of them, they may escape liability under the “learned intermediary” doctrine—a legal principle holding that manufacturers satisfy their duty to warn when they warn the treating physician, even if the patient is not directly informed. The success of Dupixent litigation will ultimately depend on whether plaintiffs can prove that manufacturers knew or should have known about cancer risks earlier than they disclosed them, and that this failure to warn caused harm.
Which Manufacturers Face Dupixent Cancer Lawsuits?
Sanofi and Regeneron Pharmaceuticals are the manufacturers named in Dupixent cancer litigation. Sanofi, a French multinational pharmaceutical company, markets and distributes Dupixent globally. Regeneron, an American biopharmaceutical company, developed Dupixent and shares profits and liability with Sanofi through their partnership.
Both manufacturers face joint claims that they failed to properly warn patients and prescribing physicians about the cancer risks associated with Dupixent use. The lawsuits allege that Sanofi and Regeneron knew or should have known about the connection between Dupixent and lymphoma risk but failed to disclose this information adequately on the drug’s label, in sales materials, or in communications with healthcare providers. As the regulatory filings and FDA signals accumulate, the manufacturers’ potential knowledge of cancer risks becomes a critical factual question. If internal company documents show that Sanofi and Regeneron were aware of lymphoma signals early on but delayed updating warnings, litigation outcomes could be substantially worse for the manufacturers than if they can demonstrate genuine ignorance of the risks until the FDA alert in March 2025.
What Is the Future Outlook for Dupixent Cancer Litigation?
The Dupixent MDL consolidation is expected to follow a familiar pattern in pharmaceutical mass tort litigation. Once formally established, the MDL will move through several phases: initial case management and scheduling orders; aggressive discovery from manufacturers’ documents; retention and reports from scientific and medical experts; potentially a bellwether trial or trials to test the strength of evidence; and then settlement negotiations if early verdicts favor plaintiffs or if both sides see value in resolving the litigation. The timeline for resolution is typically years away.
Large MDLs involving cancer causation generally require 3 to 7 years from consolidation to settlement or final trial verdicts, depending on the complexity of the science and the number of cases. For Dupixent, if the MDL is formally established in mid-2026, injured patients and their attorneys should anticipate that initial resolution discussions might not occur until 2028 or 2029, with final settlements or verdicts following afterward. This extended timeline means patients injured by Dupixent should consult with attorneys promptly—not only to preserve evidence and meet statutes of limitation, but to ensure their cases are included in the MDL before it becomes unwieldy with thousands of claims.
Conclusion
Drug makers Sanofi and Regeneron Pharmaceuticals have agreed to consolidate Dupixent cancer lawsuits in a federal multidistrict litigation, with the Northern District of Georgia identified as the appropriate venue. This consolidation reflects both the accumulation of cases in Georgia and the recognition that streamlined litigation through an MDL is more efficient than trying dozens of similar cases across multiple courts. The litigation stems from compelling evidence: the FDA identified over 300 reports of cutaneous T-cell lymphoma linked to Dupixent in March 2025, with a reported rate 30 times higher than other medications, and independent research found Dupixent users faced a 4.5-fold increased risk of T and NK cell lymphomas.
If you or a family member has developed lymphoma after using Dupixent, you should consult with a qualified attorney immediately to discuss whether you have a potential claim. The litigation is still in its earliest stages, and no verdicts or settlements have been reached, but the MDL consolidation suggests the courts and manufacturers are preparing for significant litigation ahead. Time is critical because statutes of limitation will eventually expire for potential claimants, and joining the MDL now ensures your case is included in the coordinated litigation rather than pursued separately.